Gewählte Publikation:
SHR
Neuro
Krebs
Kardio
Lipid
Stoffw
Microb
Bettermann, K; Benesch, M; Weis, S; Haybaeck, J.
SUMOylation in carcinogenesis.
Cancer Lett. 2012; 316(2):113-125
Doi: 10.1016/j.canlet.2011.10.036
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
-
Bettermann Kira
-
Haybäck Johannes
- Co-Autor*innen der Med Uni Graz
-
Benesch Martin
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- SUMOylation is a post-translational modification characterized by covalent and reversible binding of small ubiquitin-like modifier (SUMO) to a target protein. In mammals, four different isoforms, termed SUMO-1, -2, -3 and -4 have been identified so far. SUMO proteins are critically involved in the modulation of nuclear organization and cell viability. Their expression is significantly increased in processes associated with carcinogenesis such as cell growth, differentiation, senescence, oxidative stress and apoptosis. Little is known about the role of SUMOylation in cancer development. Therefore the present review focuses on possible implications of SUMOylation in carcinogenesis highlighting its impact as an important regulatory cell cycle protein. Moreover, novel opportunities for therapeutic approaches are discussed. The differential expression levels, the target protein preferences and the function of the SUMO pathway in different cancer subtypes raises unexpected issues questioning our understanding of the implication of SUMO in carcinogenesis. Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.
- Find related publications in this database (using NLM MeSH Indexing)
-
Animals -
-
Cell Differentiation -
-
Cell Transformation, Neoplastic - metabolism
-
Humans -
-
Signal Transduction -
-
Small Ubiquitin-Related Modifier Proteins - metabolism
-
Sumoylation - physiology
-
Ubiquitin - genetics
- Find related publications in this database (Keywords)
-
SUMO
-
Cancer
-
Ubiquitin